Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer

25 May 2023

Abstract excerpt

Inflammatory myofibroblastic tumors (IMTs) are intermediate-grade mesenchymal neoplasms commonly characterized by chromosomal rearrangements causing constitutive activation of anaplastic lymphoma kinase (ALK) and/or ALK mutations causing reduced sensitivity to ALK tyrosine kinase inhibitors (TKI). We present a patient with an IMT who initially responded to first-line alectinib, but who later suffered disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to IgG4-Related and Inflammatory Diseases
Share to Lung Cancer Research Studies
Share to Neuroendocrine Tumor Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37255276
DOI: 10.1093/oncolo/oyad129

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic CancerPMID 37255276Read ↗

Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to CrizotinibSemantic proximity Read ↗

An Inflammatory Myofibroblastic Tumor With a Novel ALKV1180L Mutation Leading to Acquired Resistance to Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsSemantic proximity Read ↗

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.Semantic proximity Read ↗

Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET RearrangementSemantic proximity Read ↗

Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.Semantic proximity Read ↗

ALK‑G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case reportSemantic proximity Read ↗

Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.Semantic proximity Read ↗

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.Semantic proximity Read ↗

ALK-Negative Lung Inflammatory Myofibroblastic Tumor in a Young Adult: a Case Report and Literature Review of Molecular AlterationsSemantic proximity Read ↗

Gene fusion involving the insulin‐like growth factor 1 receptor in an ALK ‐negative inflammatory myofibroblastic tumourSemantic proximity Read ↗

Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.